Poster Abstract: Based on the clinical and commercial success of SARS-CoV-2 mRNA vaccines, interest in using lipid nanoparticle-formulated mRNA (LNP-mRNA) as a next generation, rapidly deployable vaccine platform has accelerated in the form of preclinical research and clinical trials. To…
The development of mRNA vaccines has been ongoing since the late 80s, but it wasn’t until the COVID-19 pandemic that this technology became widely recognized. Instead of using an antigen to trigger the body’s immune system to create a new…
Vernal’s mission has always been to democratize access to mRNA. One of the ways we are achieving this is expanding our capabilities in mRNA process and development so that we can provide GMP for clinical use cases. Take a look…
Download the Poster – Complete the Form Below
Vernal is proud to be the Silver Sponsor for this exciting event! Connect with one of Vernal’s experts on November 8-10, 2022 in Boston and meet them at our booth. We want to know about your mRNA and LNP projects,…
Vernal Biosciences is excited to announce the start of construction on its new, 23,000 square foot mRNA manufacturing facility in Essex Junction, Vt. The new facility will include state-of-the-art equipment and clean rooms to support clinical mRNA and LNP mRNA…